Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Core Insights - Immuthera, in collaboration with PolTREG, is establishing a Scientific Advisory Board (SAB) composed of leading experts to enhance its research and development in diabetes and immunotherapy [2][3][6] - The SAB includes distinguished scientists Dr. Jay Skyler, Dr. Desmond Schatz, and Dr. Lawrence Steinman, who bring extensive experience and innovative approaches to the field [5][7][8] - Immuthera aims to develop a pipeline of Treg cell therapies for autoimmune and neuroinflammatory diseases, leveraging the expertise of its SAB and partnerships with US academic centers [4][6][9] Company Overview - Immuthera is focused on pioneering cell-based therapies for autoimmune diseases, with plans to develop assets initially created by PolTREG under the US FDA regulatory framework [7] - The company is actively seeking investment to support the manufacture and clinical development of its therapies in the United States [7] Scientific Advisory Board Highlights - Dr. Jay Skyler is recognized for his contributions to modern diabetes care, including pioneering intensive insulin therapy and leading major clinical trials [5][8] - Dr. Desmond Schatz has dedicated his career to understanding type 1 diabetes, particularly in children, and has led significant research initiatives [7][8] - Dr. Lawrence Steinman is noted for his groundbreaking work in neuroimmunology and the development of therapies for autoimmune diseases, including multiple sclerosis [7][8] Collaboration and Development - Immuthera will collaborate closely with PolTREG and leading US academic institutions to advance its Treg cell therapy pipeline [4][6][9] - PolTREG's lead product, PTG-007, is an autologous Treg treatment for early-onset Type-1 Diabetes, which is ready for Phase 2/3 clinical testing [9]